China Prescription Drug 2009 Issue 9 Opportunities and Challenges in Early Clinical Studies of Innovate Drugs

Opportunities and Challenges in Early Clinical Studies of Innovate Drugs
li hai yan

..............page:8

zhong shi ke xue de yao wu lin chuang shi yan
xu jun cai

..............page:10

wei xin yao jin kou yao fang ke ji shu zhuan rang yao pin ji shu zhuan rang zhu ce guan li gui ding chu tai , huo jiang yin fa xin yi lun you sheng lie tai
xian yun

..............page:12

xin zuo pian zhen shi shi jie yan jiu xiang mu qi dong
zeng shi

..............page:13

Introduction of Draft on Guidelines for Ethic Review
zhong zhen hua

..............page:14

Essential Drug List and Essential Drug System Publicized and Implemented
liu zheng wu

..............page:15

pu la ge lei lin chuang jia zhi fen xi
deepal;l.bhatt; hai yan

..............page:18

mian yi diao jie ,1 xing tang niao bing de wei lai
peter;chang; hai yan

..............page:19

Drug Codevelopment: The World Is Flat
mao dong lei

..............page:22

chuang xin ke yi fa sheng zai ren he yi ge jiao luo
mao dong lei

..............page:27

da yao qi yue kong huang , sheng wu ji shu gong si qian jing yue guang ming
tracy;lefteroff;mark;simon;attila;karacsony; yao li xin

..............page:28

fda 483 bao gao ying dui ce lue yan jiu
liu yu jun ; liang yi

..............page:30

Clinical Trial Assessment Criterions and AASLD Practice Guidelines: Management of Hepatocellular Carcinoma
qin shu zuo

..............page:33

Sharpen Tools for Good Jobs-Evaluation on Hypoglycemic Efficacy and Safety of Rosiglitazone in the Past 10 Years
lu ju ming

..............page:36

qian lie xian ai nei fen mi zhi liao de li shi yu xian zhuang
guan you yan ; zhao xin ; ma jian hui

..............page:39

que xue xing xin nao xue guan ji bing , ri jian zeng chang de wei xie
zhong zhen hua

..............page:46

New Concepts in Anticoagulant and Thrombolytic Therapy for Cardiovascular Diseases
shi zhong wei

..............page:49

xue shuan , dai jie de mi jin rong shuan yao wu lin chuang shi yong gai kuang
pan li

..............page:52

cong shu xue tong kan zhong yao zhu she ji de ti qu gong yi he zhi liang kong zhi
yu li

..............page:54

xue kang kou fu ye lin chuang ying yong jin zhan

..............page:59

Features in Clinical Trial Protocol Design
fan da chao

..............page:60

Lou Jing:Step Forward in Biopharma
pan li

..............page:62

Interpretation and Reflection on Fast Tract Review in Drug Registration in Developed Countries
zhang ke jian

..............page:66

zhui zhu de bi an
mao dong lei

..............page:1

denosumab dui jue yi hou gu zhi shu song fu nv fa sheng gu zhe de yu fang zuo yong
cummings;sr;sand;martin;j;mcclung;mr

..............page:42

patrici yan jiu :hpv-16/18as04 zuo ji yi miao yu fang hpv xiang guan gong jing ai qian bing bian xiao guo guan cha
j;paavonen;p;naud;j;salmer n

..............page:42

a si pi lin yu jie zhi chang ai cun huo lv de guan xi
chan;at;ogino;s;fuchs;cs

..............page:43

ju yi er chun gan rao su -2b huo -2a yu li ma wei lin lian he zhi liao bing xing gan yan liao xiao bi jiao
mchutchison;jg;lawitz;ej;shiffman;ml

..............page:43

zuo ge lie tong yu luo ge tong dui tang niao bing huan zhe xin xue guan shi jian fa sheng de ying xiang
jour;link;dn;gomes;t;lipscombe;ll

..............page:45

mega yan jiu : fu fang kou fu bi yun yao dui jing mai xue jian fa sheng de ying xiang
van;hylckama;vlieg;a;helmerhorst;fm;vandenbroucke;jp; yin hui juan ; li tian xing

..............page:45